Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches
Open accessThe DOI matches its Crossref record; 114 of the 115 references it cites were found in a registry or an index.
Abstract
: Some medications have a small positive effect on reducing PTSD symptom severity and can be considered as potential monotherapy treatments; these include fluoxetine, paroxetine, sertraline, venlafaxine and quetiapine. Two medications, prazosin and risperidone, also have a small positive effect when used to augment pharmacological monotherapy. There was no evidence of superiority for one intervention over another in the small number of head-to-head comparison studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psychopharmacological interventions are also effective evidence-based treatments for non-comorbid EDs, PTSD and related comorbid disorders, e.g., mood and anxiety disorders, but they should always be adjunctive to psychotherapeutic interventions for patients with ED + PTSD and related comorbidities (174–179) (see #9 in Figure 1).”
From The integrated treatment of eating disorders, posttraumatic stress disorder, and psychiatric comorbidity: a commentary on the evolution of principles and guidelines (2023) · cites this paper as [178]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders, 5th ed.
Carter, M. J. (2014) · Therapeutic Recreation Journal · Cited by 15,169
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052 · cited 1×
“It causes considerable distress and runs a chronic course in around a third of individuals (Kessler, Chiu, Demler, Merikangas, & Walters, 2005); keeping them off work, in receipt of long-term incapacity benefits and requiring support from medical services for many years (Ferry et al., 2008).”
BackgroundPosttraumatic Stress Disorder in the National Comorbidity Survey
Kessler, R. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240066012 · Cited by 10,379 · cited 2×
“In conflict-afflicted areas, the prevalence is much higher, between 13% and 25% (Steel et al., 2009), and reaches more than 50% in survivors of sexual assault (Kessler, Sonnega, Bromet, Hughes, & Nelson, 1996).”
BackgroundCONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
Steel, Z., Chey, T., Silove, D., Marnane, C., Bryant, R. A., & van Ommeren, M. (2009) · JAMA · doi:10.1001/jama.2009.1132 · Cited by 2,246 · cited 1×
“In conflict-afflicted areas, the prevalence is much higher, between 13% and 25% (Steel et al., 2009), and reaches more than 50% in survivors of sexual assault (Kessler, Sonnega, Bromet, Hughes, & Nelson, 1996).”
BackgroundCONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., & Moher, D. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72352 · Cited by 2,165
Wang, P. S., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., Borges, G., Bromet, E. J., Bruffaerts, R., de Girolamo, G., de Graaf, R., Gureje, O., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61414-7 · Cited by 1,655 · cited 2×
“In addition to concerns about the tolerability and efficacy of TFPT, people with PTSD may live in areas of the world without access to it or, where they can access it, face long waiting lists for therapy, keeping them off work, in receipt of long-term incapacity benefits and requiring medical support (Wang et al., 200…”
BackgroundThe Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988
Pietrzak, R. H., Goldstein, R. B., Southwick, S. M., & Grant, B. F. (2011) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2010.11.010 · Cited by 963 · cited 1×
“PTSD is also associated with high rates of debilitating comorbidities, with up to 50% suffering from depression (Pietrzak, Goldstein, Southwick, & Grant, 2011) and drug and alcohol abuse (Roberts, Kitchiner, Kenardy, & Bisson, 2010), and 19% will attempt suicide (Kessler et al., 1996).”
Background
Research works printed but not linked: 9
- Ferry, F., Bolton, D., Bunting, B., Devine, B., McCann, S., & Murphy, S. (2008). Trauma, health and conflict in Northern Ireland: A study of the epidemiology of trauma related disorders and qualitative investigation of the impact of trauma on the individual. Ireland: Psychology Research Institute, University of Ulster.
- Forman-Hoffman, V., Middleton, J. C., Feltner, C., Gaynes, B. N., Weber, R. P., Bann, C., … Green, J. (2018b). Psychological and pharmacological treatments for adults with posttraumatic stress disorder: A systematic review update, agency for healthcare research and quality. PMID: 30204376.
- Higgins, J. P. T., & Green, S. (2011). Cochrane handbook for systematic reviews of interventions version 5.1.0. UK: The Cochrane Collaboration and John Wiley and Sons Ltd.
- National Institute for Health and Care Excellence Guideline: Post-traumatic stress disorder. (2018, June). Draft for consultation. UK: NICE.
- Review Manager (RevMan) (2014) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre The Cochrane Collaboration.
- 10.1521/psyc.2008.71.2.134168 · doi:10.1521/psyc.2008.71.2.134168
- SKB627, Bryson, H., Lawrinson, S., GJ, E., & KM, G. (unpublished). A 12 week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder.
- SKB650, Bryson, H., KE, D., & Jeffery, P. J. (unpublished). A study of the maintained efficacy and safety of paroxetine versus placebo in the long-term treatment of posttraumatic stress disorder.
- Sonne, S. C., Waldrop, A., Back, S., Killeen, T., McRae, A., & Brady, K. (2006) Paxil CR versus placebo in the treatment of outpatients with comorbid PTSD and substance dependence, Proceedings of the 68th Annual Scientific Meeting of the College on Problems of Drug Dependence, June 17-22; Scottsdale, Arizona.
Cited by
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault-Phillips, S., Nijdam, M. J., McFarlane, A., & Vermetten, E. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 208
Prevention and treatment of PTSD: the current evidence base
Bisson, J. I., & Olff, M. (2021) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1824381 · Cited by 148
“Pharmacological treatment of adults with PTSD (Hoskins et al., 2020).”
Self-citationBrewin, C. R., Atwoli, L., Bisson, J. I., Galea, S., Koenen, K. C., & Lewis‐Fernández, R. (2025) · World Psychiatry · doi:10.1002/wps.21269 · Cited by 139
“Most guidelines do not consider augmentation, although systematic reviews and meta-analyses provide some evidence to support augmentation of either SSRIs or venlafaxine with the alpha1-adrenoceptor antagonist prazosin 364 .”
Self-citationAstill Wright, L., Horstmann, L., Holmes, E. A., & Bisson, J. I. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01570-w · Cited by 97
Self-citationPost-traumatic Stress Disorder
Merians, A. N., Spiller, T. R., Harpaz‐Rotem, I., Krystal, J. H., & Pietrzak, R. H. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.04.003 · Cited by 129
Metadata
- Authors
- Hoskins, M. D., Bridges, J., Sinnerton, R., Nakamura, A., Underwood, J. F. G., Slater, A., Lee, M. R. D., Clarke, L., Lewis, C., Roberts, N. P., & Bisson, J. I.
- Affiliations
- Cardiff University (GB)
- Corresponding author
- Hoskins, Mathew D.
- Venue
- European Journal of Psychotraumatology
- Publisher
- Informa UK Limited
- Published
- 2021-01
- Volume
- 12
- Issue
- 1
- Pages
- 1802920-1802920
- ISSN
- 2000-8066 (ISSN-L)
- PMC
- PMC8725683
- OpenAlex
- W3123716570
- Cited by
- 127
- References
- 115
- Citations by year
- 2026: 23 · 2025: 32 · 2024: 27 · 2023: 22 · 2022: 16 · 2021: 6
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- European Journal of Psychotraumatology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- The International Society for Traumatic Stress Studies
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Social Sciences › Psychology › Clinical Psychology › Migration, Health and Trauma
- Keywords
- post-traumatic stress disorder, pharmacotherapy, monotherapy, augmentation therapy, fluoxetine, paroxetine, sertraline, venlafaxine, quetiapine, prazosin, risperidone, symptom severity, head-to-head comparison
- MeSH terms
- Drug Synergism, Drug Therapy, Combination, Humans, Stress Disorders, Post-Traumatic, Antipsychotic Agents, Selective Serotonin Reuptake Inhibitors, Adrenergic alpha-1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. https://app.cochat.ai/papers/10.1080/20008198.2020.1802920
- The paper
- Hoskins, M. D., Bridges, J., Sinnerton, R., Nakamura, A., Underwood, J. F. G., Slater, A., Lee, M. R. D., Clarke, L., Lewis, C., Roberts, N. P., & Bisson, J. I. (2021). Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. European Journal of Psychotraumatology. https://doi.org/10.1080/20008198.2020.1802920
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.